Helicobacter pylori infection and inflammatory bowel disease: is there a link?

Maryam Nejabat, Saeid Amiri Zadeh Fard, Alireza Safarpour, Somayeh Ahmadpour Jirandeh

Abstract


Inflammatory bowel disease (IBD) that include Crohn´s Disease (CD) and Ulcerative colitis (UC) are types of digestive system disease that steel have not been properly identified as their original causes. Our goal was to evaluation of lower infection with H.pylori in patients suffer from IBD in compete with the normal population. Method: IN this case-control study 146 patients with IBD (32 with CD and 114 with UC) and 146 volunteers donated blood as control group were tested for IgG and IgA antibody against H.pylori since Dec 2017 from May 2018 in Shiraz that were randomly selected  from IBD registry software in motahari clinic. Result: The presence of H.pyloriIgG  was confirmed in 10 (31.2%) of CD, 37 (32.4%) of patients with ulcerative colitis and 105 (71.9%) of the control group that it was significant (P< 0.001).The presence of H.pylori IgA  was confirmed in 25%of CD, 31.6% of patients with UC and 40.4% of the control group that it was not significant. In order to relation between IBD treatment regimens and presence of H.pylori IgG, there was significant differences between patients who received immune-modulator and immune-suppressive drugs and whom were not used these drugs.(p< 0.001). Conclusion: Our results show that the prevalence of serum IgG antibody against H pylori was significantly lower in patients with IBD than in controls. The use of immune-modulator and immune-suppressive drugs may reduce the involvement of IBD patients with Helicobacter pylori infection.


Keywords


Inflammatory bowel disease, Crohn´s disease, Ulcerative colitis, H.pylori , Immuno-suppressive

Full Text:

PDF

References


Baumgart DC, Bernstein CN, Abbas Z, Colombel JF, Day AS, D'Haens G, et al. IBD Around the world: comparing the epidemiology, diagnosis, and treatment: proceedings of the World Digestive Health Day 2010--Inflammatory Bowel Disease Task Force meeting. Inflamm Bowel Dis. 2011;17:639-44. doi: 10.1002/ibd.21409. PubMed PMID: 20725944.

Ko Y, Butcher R, Leong RW. Epidemiological studies of migration and environmental risk factors in the inflammatory bowel diseases. World J Gastroenterol. 2014;20:1238-47. doi: 10.3748/wjg.v20.i5.1238. PubMed PMID: 24574798; PubMed Central PMCID: PMCPMC3921506.

Fengming Y, Jianbing W. Biomarkers of inflammatory bowel disease. Dis Markers. 2014;2014:710915. doi: 10.1155/2014/710915. PubMed PMID: 24963213; PubMed Central PMCID: PMCPMC4055235.

JVV Antúnez (2016). Hipótesis para un derecho alternativo desde la perspectiva latinoamericana. Opción 32 (13), 7-10.

Giaffer MH, Holdsworth CD, Duerden BI. Virulence properties of Escherichia coli strains isolated from patients with inflammatory bowel disease. Gut. 1992;33:646-50. PubMed PMID: 1612481; PubMed Central PMCID: PMCPMC1379295.

Zhang YZ, Li YY. Inflammatory bowel disease: pathogenesis. World J Gastroenterol. 2014;20:91-9. doi: 10.3748/wjg.v20.i1.91. PubMed PMID: 24415861; PubMed Central PMCID: PMCPMC3886036.

Gradel KO, Nielsen HL, Schonheyder HC, Ejlertsen T, Kristensen B, Nielsen H. Increased short- and long-term risk of inflammatory bowel disease after salmonella or campylobacter gastroenteritis. Gastroenterology. 2009;137:495-501. doi: 10.1053/j.gastro.2009.04.001. PubMed PMID: 19361507.

Sonnenberg A. Review article: historic changes of Helicobacter pylori-associated diseases. Aliment Pharmacol Ther. 2013;38:329-42. doi: 10.1111/apt.12380. PubMed PMID: 23786250.

M Nurgaliyeva, A Auyezova, A Kosmuratova (2018). Revisiting the role of independence formation and organizing individual work of the student in the educational process of HEI. Opción, Año 33, No. 85 (2018): 290-307.

Willison HJ. Gangliosides as targets for autoimmune injury to the nervous system. Journal of neurochemistry. 2007;103:143-9.

Kaakoush NO, Holmes J, Octavia S, Man SM, Zhang L, Castano-Rodriguez N, et al. Detection of Helicobacteraceae in intestinal biopsies of children with Crohn's disease. Helicobacter. 2010;15:549-57. doi: 10.1111/j.1523-5378.2010.00792.x. PubMed PMID: 21073612.

Naito M, Frirdich E, Fields JA, Pryjma M, Li J, Cameron A, et al. Effects of sequential Campylobacter jejuni 81-176 lipooligosaccharide core truncations on biofilm formation, stress survival, and pathogenesis. Journal of bacteriology. 2010;192:2182-92.

van Amsterdam K, van Vliet AH, Kusters JG, van der Ende A. Of microbe and man: determinants of Helicobacter pylori-related diseases. FEMS Microbiol Rev. 2006;30:131-56. doi: 10.1111/j.1574-6976.2005.00006.x. PubMed PMID: 16438683.

Magen E, Delgado JS. Helicobacter pylori and skin autoimmune diseases. World J Gastroenterol. 2014;20:1510-6. doi: 10.3748/wjg.v20.i6.1510. PubMed PMID: 24587626; PubMed Central PMCID: PMCPMC3925859.

Reibman J, Marmor M, Filner J, Fernandez-Beros ME, Rogers L, Perez-Perez GI, et al. Asthma is inversely associated with Helicobacter pylori status in an urban population. PLoS One. 2008;3:e4060. doi: 10.1371/journal.pone.0004060. PubMed PMID: 19112508; PubMed Central PMCID: PMCPMC2603593.

Krause I, Anaya JM, Fraser A, Barzilai O, Ram M, Abad V, et al. Anti-infectious antibodies and autoimmune-associated autoantibodies in patients with type I diabetes mellitus and their close family members. Ann N Y Acad Sci. 2009;1173:633-9. doi: 10.1111/j.1749-6632.2009.04619.x. PubMed PMID: 19758209.

Thia KT, Loftus EV, Jr., Sandborn WJ, Yang SK. An update on the epidemiology of inflammatory bowel disease in Asia. Am J Gastroenterol. 2008;103:3167-82. doi: 10.1111/j.1572-0241.2008.02158.x. PubMed PMID: 19086963.

Koloski NA, Bret L, Radford-Smith G. Hygiene hypothesis in inflammatory bowel disease: a critical review of the literature. World J Gastroenterol. 2008;14:165-73. PubMed PMID: 18186549; PubMed Central PMCID: PMCPMC2675108.

Roka K, Roubani A, Stefanaki K, Panayotou I, Roma E, Chouliaras G. The prevalence of Helicobacter pylori gastritis in newly diagnosed children with inflammatory bowel disease. Helicobacter. 2014;19:400-5. doi: 10.1111/hel.12141. PubMed PMID: 24827117.

Caner S, Altinbas A, Yesil Y, Beyazit Y, Yilmaz B, Yuksel O. The relation between Helicobacter pylori and ulcerative colitis. Turk J Med Sci. 2014;44:820-3. PubMed PMID: 25539552.

Xiang Z, Chen YP, Ye YF, Ma KF, Chen SH, Zheng L, et al. Helicobacter pylori and Crohn's disease: a retrospective single-center study from China. World J Gastroenterol. 2013;19:4576-81. doi: 10.3748/wjg.v19.i28.4576. PubMed PMID: 23901235; PubMed Central PMCID: PMCPMC3725384.

Lundgren A, Stromberg E, Sjoling A, Lindholm C, Enarsson K, Edebo A, et al. Mucosal FOXP3-expressing CD4+ CD25high regulatory T cells in Helicobacter pylori-infected patients. Infect Immun. 2005;73:523-31. doi: 10.1128/iai.73.1.523-531.2005. PubMed PMID: 15618192; PubMed Central PMCID: PMCPMC538965.

Rad R, Brenner L, Bauer S, Schwendy S, Layland L, da Costa CP, et al. CD25+/Foxp3+ T cells regulate gastric inflammation and Helicobacter pylori colonization in vivo. Gastroenterology. 2006;131:525-37. doi: 10.1053/j.gastro.2006.05.001. PubMed PMID: 16890606.

Wehkamp J, Fellermann K, Herrlinger KR, Bevins CL, Stange EF. Mechanisms of disease: defensins in gastrointestinal diseases. Nat Clin Pract Gastroenterol Hepatol. 2005;2:406-15. doi: 10.1038/ncpgasthep0265. PubMed PMID: 16265431.

el-Omar E, Penman I, Cruikshank G, Dover S, Banerjee S, Williams C, et al. Low prevalence of Helicobacter pylori in inflammatory bowel disease: association with sulphasalazine. Gut. 1994;35:1385-8. PubMed PMID: 7959192; PubMed Central PMCID: PMCPMC1375010.

Pearce CB, Duncan HD, Timmis L, Green JR. Assessment of the prevalence of infection with Helicobacter pylori in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2000;12:439-43. PubMed PMID: 10783998.

Piodi LP, Bardella M, Rocchia C, Cesana BM, Baldassarri A, Quatrini M. Possible protective effect of 5-aminosalicylic acid on Helicobacter pylori infection in patients with inflammatory bowel disease. J Clin Gastroenterol. 2003;36:22-5. PubMed PMID: 12488702.

Wagtmans MJ, Witte AM, Taylor DR, Biemond I, Veenendaal RA, Verspaget HW, et al. Low seroprevalence of Helicobacter pylori antibodies in historical sera of patients with Crohn's disease. Scand J Gastroenterol. 1997;32:712-8. PubMed PMID: 9246713.

Parente F, Molteni P, Bollani S, Maconi G, Vago L, Duca PG, et al. Prevalence of Helicobacter pylori infection and related upper gastrointestinal lesions in patients with inflammatory bowel diseases. A cross-sectional study with matching. Scand J Gastroenterol. 1997;32:1140-6. PubMed PMID: 9399396.

Murad HA. Does Helicobacter pylori eradication therapy trigger or protect against Crohn's disease? Acta Gastroenterol Belg. 2016;79:349-54. PubMed PMID: 27821031.

Smolka AJ, Backert S. How Helicobacter pylori infection controls gastric acid secretion. J Gastroenterol. 2012;47:609-18. doi: 10.1007/s00535-012-0592-1. PubMed PMID: 22565637.

Stenson WF, Mehta J, Spilberg I. Sulfasalazine inhibition of binding of N-formyl-methionyl-leucyl-phenylalanine (FMLP) to its receptor on human neutrophils. Biochem Pharmacol. 1984;33:407-12. PubMed PMID: 6142713.

Taha AS, Sturrock RD, Russell RI. Helicobacter pylori and peptic ulcers in rheumatoid arthritis patients receiving gold, sulfasalazine, and nonsteroidal anti-inflammatory drugs. Am J Gastroenterol. 1992;87:1732-5. PubMed PMID: 1360191.


Refbacks

  • There are currently no refbacks.




Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Revista Publicando.

Licencia de Creative Commons

 

This Content is available under licencia de Creative Commons Reconocimiento-NoComercial-CompartirIgual 4.0 Internacional.